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ABSTRACT Several enzymes are involved in fatty acid oxidation, which is a key process in mitochondrial
energy production. Inherited defects affecting any step of fatty acid oxidation can result in clinical disease.
We present here an extended family of German Hunting Terriers with 10 dogs affected by clinical signs of
exercise induced weakness, muscle pain, and suspected rhabdomyolysis. The combination of clinical signs,
muscle histopathology and acylcarnitine analysis with an elevated tetradecenoylcarnitine (C14:1) peak
suggested a possible diagnosis of acyl-CoA dehydrogenase very long chain deﬁciency (ACADVLD). Whole
genome sequence analysis of one affected dog and 191 controls revealed a nonsense variant in the ACADVL
gene encoding acyl-CoA dehydrogenase very long chain, c.1728C.A or p.(Tyr576). The variant showed perfect
association with the phenotype in the 10 affected and more than 500 control dogs of various breeds. Pathogenic
variants in the ACADVL gene have been reported in humans with similar myopathic phenotypes. We therefore
considered the detected variant to be the most likely candidate causative variant for the observed exercise
induced myopathy. To our knowledge, this is the ﬁrst description of this disease in dogs, which we propose to
name exercise induced metabolic myopathy (EIMM), and the identiﬁcation of the ﬁrst canine pathogenic
ACADVL variant. Our ﬁndings provide a large animal model for a known human disease and will enable genetic
testing to avoid the unintentional breeding of affected offspring.
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Mitochondrial b-oxidation of fatty acids is one of the major sources of
cellular energy, in particular in organs with a high metabolic rate such
as heart, liver and skeletal muscle. During fasting or prolonged exercise,
ketone bodies produced in the liver become the major source to meet
energy requirements (Andresen et al. 1999; Bartlett and Eaton 2004;
Hisahara et al. 2015) whereby long-chain fatty acids are released from
triglycerides in fat tissue and activated to acyl-CoA esters. The inner
mitochondrial membrane is impermeable to long-chain fatty acids
which are transported into the mitochondria via the carnitine shuttle.
Carnitine is transported into cells by a high-afﬁnity carnitine trans-
porter. Within the mitochondria, several chain-length speciﬁc enzymes
shorten acyl-CoA by two carbon atoms (one acetyl-CoA) in subsequent
b-oxidation cycles. Most of the long-chain speciﬁc enzymes are asso-
ciated with the inner mitochondrial membrane (Ogilvie et al. 1994;
Souri et al. 1996; Souri et al. 1998; Andresen et al. 1999; Fukao et al.
2001; Bartlett and Eaton 2004; Goetzman et al. 2007; McAndrew et al.
2008; Liang and Nishino 2011; Schiff et al. 2013; Zhang et al. 2014;
Miller et al. 2015).
Inherited disorders of mitochondrial b-oxidation can present with
great variability. In humans, insufﬁcient ketone body production dur-
ing catabolic states (prolonged fasting, surgery, infection etc.) may
cause hypoketotic hypoglycemic coma sometimes accompanied by
signs of hepatic failure. Accumulation of toxic long-chain acylcarni-
tines, particularly in long-chain fatty acid oxidation disorders, may
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cause lactic acidosis, cardiomyopathy and hepatopathy similar to some
mitochondriopathies. Milder deﬁciency variants of long-chain fatty
acid oxidation and the carnitine shuttle may affect skeletal muscle
and manifest as chronic weakness, myalgia or rhabdomyolysis
(Zschocke and Hoffmann 2011).
In humans, acyl-CoA dehydrogenase very long-chain deﬁciency
(ACADVLD; OMIM 201475) is considered to be the most common
inherited disorder of mitochondrial long-chain fatty acid oxidation
(Tucci 2017). The acyl-CoAdehydrogenase very long chain (ACADVL;
EC 1.3.8.9) is speciﬁc for fatty acids with 16 to 20 carbon atoms and is
encoded by the nuclear ACADVL gene. While all other acyl-CoA de-
hydrogenase family members form homotetrameric structures with a
monomer size of about 45 kD, ACADVL is a homodimer with amono-
mer size of about 67 kD due to an extended 180 amino acid C-terminal
region, which plays a role in maintaining the quaternary structure and
mediates the interactions with the inner mitochondrial membrane
(Souri et al. 1996; Souri et al. 1998; Goetzman et al. 2007; McAndrew
et al. 2008; Schiff et al. 2013).
Deﬁciency of ACADVL (ACADVLD) in humans is an autosomal
recessive inherited disorder with considerable allelic heterogeneity and
more than one hundred pathogenic variants in the human ACADVL
gene have been reported until now (Zhang et al. 2014; Miller et al.
2015). The ﬁrst human patient was identiﬁed as early as 1985 before
the era of molecular genetics and the identiﬁcation of the ACADVL
gene (Hale et al. 1985; Izai et al. 1992; Uchida et al. 1992; Souri et al.
1996). The clinical phenotype is quite variable with respect to the
severity of clinical signs and age of onset. Human ACADVLD can be
subdivided into three major clinical forms (Andresen et al. 1999; Miller
et al. 2015). A severe neonatal onset form presents shortly after birth
with hepatic encephalopathy, Reye-like syndrome, and cardiomyopa-
thy leading to a high mortality. The infantile onset form usually pre-
sents with recurrent hypoketotic hypoglycemia and liver dysfunction.
The adult-onset form, which occurs during adolescence or later, pre-
sents mainly with muscle signs which include myalgia, weakness, epi-
sodes of rhabdomyolysis, intermittent or permanently elevated plasma
creatine kinase levels and myoglobinuria. Symptoms are triggered by
stress such as physical exercise, fasting or cold exposure (Ogilvie et al.
1994; Souri et al. 1998; Saudubray et al. 1999; Fukao et al. 2001; Wood
et al. 2001; Goetzman et al. 2007; Liang and Nishino 2011; Schiff et al.
2013; Tucci et al. 2014; Zhang et al. 2014; Miller et al. 2015). Histo-
pathological examination of patients suffering from ACADVLD dem-
onstrates the accumulation of lipid droplets within muscles ﬁbers.
Therefore, the adult-onset form of ACADVLD may be included in
the group of lipid storage induced myopathies (Liang and Nishino
2010; Liang and Nishino 2011).
Elevated tetradecenoylcarnitine(C14:1) isusedasabiomarker for the
disease. In human medicine, newborn screening based on the levels of
acylcarnitines and especially tetradecenoylcarnitine (C14:1) in dried
blood spots is widely used to diagnose ACADVLD (Wood et al. 2001;
Zytkovicz et al. 2001; Lindner et al. 2010; Miller et al. 2015).
In dogs, cases of myopathies have been reported with features
suggestive of defects in oxidative metabolism (Platt et al. 1999;
Biegen et al. 2015), but to the best of our knowledge, no genetic variant
has been identiﬁed so far. Recently, breeders noticed several cases of
exercise induced muscle pain and weakness in German Hunting Ter-
riers. The aim of the present study was the characterization of this
phenotype, which we term exercise induced metabolic myopathy
(EIMM) and the identiﬁcation of the presumed causative genetic
variant.
MATERIALS AND METHODS
Ethics statement
The dogs in this study were examined with the consent of their owners.
Blood samples were collected with the approval of the Cantonal Com-
mittee for Animal Experiments (Canton of Bern; permit BE75/16). All
animal experiments were done in accordance with local laws and
regulations.
Breed nomenclature
TheFederationCynologique Internationale (FCI) describes theGerman
HuntingTerrier dog as a compact, well-muscled and hardy hunting dog
breed (FCI-st. N 103/26.05.2015). In this paper, all references to the
breed correspond to the FCI standards.
Animal selection for phenotyping
For the phenotype analyses, German Hunting Terriers with signs of
exercise induced intolerance were examined. Control animals consisted
of German Hunting Terriers without any signs of exercise induced
intolerance, which were presented at the Veterinary Clinic for Small
Animals Trier, Germany, for routine medical examinations.
Clinical examinations
Clinical, neurological and laboratory examinations of dogs were per-
formed at theVeterinaryClinic for Small Animals, Trier, Germany, by a
speciﬁcally trained thesis student (FM)andaDiplomateof theEuropean
College forVeterinaryNeurology (MK) tocharacterize thephenotypeof
a novel disease associated with exercise intolerance in GermanHunting
Terriers.Cases consistedofnineGermanHuntingTerrierswithahistory
of exercise induced weakness, myalgia and pigmenturia. Controls in-
cluded 14 German Hunting Terrier dogs without signs of exercise
intolerance.Oneaffecteddogdiedduring the study for reasonsunrelated
to the described novel disease. Therefore, laboratoryﬁndings could only
be evaluated in eight affected dogs. Clinical signs and their history after
different levels of exercise were further evaluated using a questionnaire
ﬁlled in by the dog owners.
Laboratory analyses
Blood samples were taken from the vena cephalica and collected in
Li-heparin (Li-H) (Micro tube Sarstedt, Germany), sodium ﬂuoride
(NaF; BD Vacutainer, Plymouth UK) and ethylenediaminetetraacetic
acid (K-EDTA Sarstedt, Germany) tubes. Using plasma from the Li-H
tube, chemistry proﬁles including the measurement of electrolytes,
hepatic enzymes and creatine kinase were obtained using the IDEXX
Catalyst Dx Chemistry Analyzer (IDEXX Laboratories, Germany).
Blood in NaF tubes was used for measuring the lactate level at the
Synlab Laboratory, Trier, Germany. Complete blood cell count was
performedusing the IDEXXProCyteDxHematologyAnalyzer (IDEXX
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laboratories, Germany) with full EDTA blood. The concentration of the
brain natriuretic peptide (BNP) was determined from EDTAplasma by
the diagnostic test Cardiopet (IDEXX Laboratories, Germany) as de-
scribed (Fox et al. 2015). An acylcarnitine proﬁle screening was per-
formed in the Screening-Labor Hannover, Germany. For this test,
EDTA blood was placed onto human newborn screening cards and
air-dried. Dried blood spots of 3.2 mm diameter were extracted with
200 ml methanol containing the deuterated internal acylcarnitine stan-
dards. After evaporation of the extracts acylcarnitines were butylated
using 50 ml of 3 N butanolic HCl at 65 for 15 min. After drying the
residue was dissolved in methanol/water 80/20, the mobile phase was
acetonitrile/water 80/20. The acylcarnitines were analyzed without
chromatographic separation in the positive ionmode, usingmultichan-
nel analyzer scan (MCA). Long-chain hydroxyacyl carnitines were
measured in positive MRM mode. The system consisted of a Waters
Micro tandem mass spectrometer equipped with electrospray ioniza-
tion (ESI) source connected with a LC pump and a PAL autosampler.
Urine samples were taken by urinary catheterization and then investi-
gated with urine dipsticks (Multistix Siemens Healthcare Diagnostics
Inc, Tarrytown, NY, USA). The urinary sediment was examined under
a microscope (Motic B Series, Motic Asia, China). All laboratory pa-
rameters are summarized in Table 1.
Biopsy procurement and examination
Muscle andnerve biopsieswere taken from two cases (JT007 and JT009)
under general anesthesia. Biopsies were taken from biceps femoris and
tibialis cranialis muscles as well as from ﬁbular nerve. Samples were
shippedonwet icebyovernight service to theneuropathology laboratory
of the Ludwig-Maximilians-Universität in Munich where they under-
went routine processing. Muscle samples were snap-frozen in isopen-
tane cooled in liquid nitrogen. Cryosections were performed and
stained with hematoxylin-eosin, periodic acid Schiff, Engel´s modiﬁed
Gomori stain and Oil Red O. Additional sections underwent enzyme
histochemistry for cytochrome oxidase (COX) and nicotinamide ade-
nine dinucleotide tetrazolium reductase (NADH-TR). Muscle ﬁber
typing was performed immunohistochemically (IHC) using murine
antibodies directed against skeletal fast myosin (clone MY-32, Sigma-
Aldrich Inc., St. Louis), secondary labeling through polymers (IMPRESS,
Linaris Inc. Freiburg) and a horseradish peroxidase-diaminobenzidine
tetrahydrochloride detection system.
Further samplesof eachmusclewereﬁxed in6.5%glutaraldehyde for
embedding in epoxy resin. Semithin sections were taken and stained
with azure IImethylenblue-safraninO for prelocalisation. Selected areas
then were cut at 50 nm thickness, mounted on copper grids, contrasted
with lead citrate and uranyl acetate for transmission electron micros-
copy (Zeiss EM 10, Jena).
Nerve samples were ﬁxed in 2.5% glutaraldehyde, contrasted with
osmium tetroxide and likewise embedded in epoxy resin. Semithin
sections were stained as mentioned above. Further pieces of osmium
stainednerveswere subjected tonerveﬁber teasing for longitudinalﬁber
examination. Procedures and diagnostic algorithms concisely have been
described, elsewhere (Gross et al. 2016).
Animal selection for genotyping
For the genetic analysis we included 120 German Hunting Terriers
consisting of 10 cases and 110 controls. The ten cases consisted of the
nine dogs that underwent the detailed clinical and laboratory examinations
and one additional dog with owner-reported exercise intolerance. Further-
more, samples from 435 dogs of 60 genetically diverse breeds, which had
been donated to the Vetsuisse Biobank, were used as controls (Table S1).
Reference sequences
All analyses were performed using the dogCanFam3.1 genome assembly
as reference sequence. Numbering within theACADVL gene refers to the
NCBI accessions XM_546581.5 (mRNA) and XP_546581.3 (protein) for
dogs and NM_000018.3 (mRNA) and NP_000009.1 (protein) for hu-
mans. The human and dog proteins both consist of 655 amino acids with
92% sequence identity.
Whole genome resequencing and variant ﬁltering
An Illumina TruSeq PCR-free library with an insert size of 350 bp was
prepared from one affected German Hunting Terrier (JT007) and
334million 2 · 150 bp paired-end reads corresponding to 37x coverage
were obtained on an Illumina HiSeq 3000 instrument. The reads were
mapped to the dog CanFam3.1 reference genome assembly and aligned
using Burrows-Wheeler Aligner version 0.7.5a with default settings (Li
andDurbin 2009). The generated SAM ﬁle was converted to a BAM ﬁle
and the reads were sorted using samtools (Li 2011). Picard tools (http://
sourceforge.net/projects/picard/) was used to mark PCR duplicates. To
perform local realignments and to produce a cleaned BAM ﬁle, we used
the GenomeAnalysis Tool Kit (GATK version 3.6.1, 50;McKenna et al.
2010). The GATK software was also used for base quality recalibration
with canine dbSNP data as training set.
Variant calling
Putative single nucleotide and small variants were identiﬁed in each
sample individually using Broad GATK HaplotypeCaller v3.6 in
gVCF mode, and subsequently jointly genotyped using Broad Geno-
typeGVCFs walker (-stand_emit_conf 20.0; -stand_call_conf 30.0);
(Van der Auwera et al. 2013). Variants were marked but not
removed using VariantFilter GATK module, based on the following
speciﬁcations: SNPs: Quality by Depth: QD , 2.0; Mapping quality:
n Table 1 Summary of different laboratory parameters and diagnostic tests
Laboratory tubes Examined parameters
Technical devices or external
laboratory
Li-heparin chemistry proﬁle (Glu, Bun, Cr, Bun/Cr, CK, Phos, Ca, TP, Alb, Glob, Alb/Glob,
ALT, ALKP, GGT, TBil, Chol, Amy, Lip)a
IDEXX Catalyst Dx
NaF lactate Synlab Laboratory Trier
K-EDTA hematology IDEXX ProCyte Dx
K-EDTA acylcarnitine screening, multichannel analyzer scan (MCA) Screening-Labor Hannover
K-EDTA brain natriuretic peptide (BNP) Cardiopet IDEXX
Urine urine speciﬁc gravity, leukocytes, nitrite, urobilinogen, protein,pH, erythrocytes,
ketones, bilirubin, glucose
Multistix Siemens Healthcare
a
Glucose (Glu), urea (Bun); creatinine (Cr); creatine kinase (CK); phosphorous (P); calcium (Ca), total protein (TP); albumin (Alb); globulin (Glob); alanine
aminotransferease (ALT); alkaline phosphatase (ALKP); gamma-glutamyltransferase (GGT); bilirubin (TBil); cholesterol (Chol); amylase (Amy); lipase (Lip)
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MQ , 40.0; Strand ﬁlter: FS . 60.0; MappingQualityRankSum:
MQRankSum , -12.5; ReadPosRankSum , -8.0. INDELs: Quality by
Depth: QD , 2.0. Strand ﬁlter: FS . 200.0. Functional effects and
genomic context of the called variants were annotated using SnpEff
(Cingolani et al. 2012) software together with the NCBI Canis lupus
familiaris Annotation Release 104. For private variant ﬁltering we used
191 control genomes. These genomes were either publicly available (Bai
et al. 2015) or produced during other previous projects (Table S2).
DNA extraction, PCR and Sanger sequencing
Genomic DNA was extracted from EDTA blood samples using the
Maxwell RSCWhole Blood DNAKit in combination with the Maxwell
RSCmachine (PromegaCorporation,Madison,WI, USA). For targeted
genotyping of the ACADVL c.1728C.A variant we used a Sanger
sequencing protocol. Speciﬁcally, PCR products were ampliﬁed from
genomic DNA using the AmpliTaqGold360Mastermix (Thermo
Fisher Scientiﬁc Corporation, Waltham, MA, USA) and primers
5‘-TCTTTATGCAGACCGTGCAG-3‘ (forward) and 5‘-ACAGG-
GAAGGTGGTGTTCAG-3‘ (reverse). After treatment with exonucle-
ase I and alkaline phosphatase, we sequenced amplicons on an ABI
3730 DNAAnalyzer (Thermo Fisher Scientiﬁc Corporation, Waltham,
MA, USA). Sanger sequences were analyzed with the Sequencher 5.1
software (Gene Codes Corporation, Ann Arbor, MI, USA).
Statistical analysis
Continuous data were expressed as median values and ranges. The data
for CK,ALT, C14:1 and lactate levelswere tested for normality using the
Shapiro Wilk test. To investigate if there were signiﬁcant differences in
the laboratory results between cases and controls Wilcoxon Rank Sum
tests were used for non-normally distributed data. We repeated these
investigations with respect to the three genotype classes (homozygous
mutant, heterozygous, homozygous wildtype) of the previously inves-
tigated dogs with Kruskal-Wallis tests. For evaluating differences be-
tween genotypes, the level of signiﬁcance was corrected for multiple
testing (z $ 2.394; P , 0.017). As the plasma lactate levels were nor-
mally distributed, a two-samples T-test and a one way ANOVA instead
of the previously mentioned tests were applied. All the statistical anal-
yses were performed using the NCSS 11 Statistical Software (NCSS,
LLC. Kaysville, UT, USA). The level of signiﬁcance was set to P, 0.05.
Data availability
Figure S1 illustrates the genotypes of the dogs from the extended family
for the ACADVL:c.1728C.A variant. Table S1 contains genotypes of
435 control dogs from 60 diverse dog breeds for the ACADVL:
c.1728C.A variant. Table S2 contains the accession numbers of the
sequenced case and the 191 control-genomes used for variant ﬁltering.
Table S3 lists the detected private variants and their functional anno-
tation in the affected German Hunting Terrier. The sequence data were
deposited under study accession PRJEB16012 and sample accession
SAMEA104125120 at the European Nucleotide Archive.
RESULTS
Clinical examination
Three female and six male affected German Hunting Terrier dogs with
an age range from 7 to 42months were examined (median 32months).
The dogs showed a history of generalizedweakness, exercise intolerance
andseverediffusemusclepain.All ownersreported, that theirdogscould
not be used for hunting, as they all collapsed and developed tetraparesis
to tetraplegia after 30 to 120 min of exercise. During these episodes, all
affected dogs presented a brownish discoloration of the urine.
On physical examination all dogs were alert and responsive. Two
dogs (JT007, JT009) were tetraparetic and palpation elicited diffuse
muscle pain. Furthermore, dog JT009 had mild muscle atrophy in the
fore- and hind limbs. None of the affected dogs had cardiac or
pulmonary abnormalities; the neurological examination did not reveal
furtherabnormalities inaddition to thepreviouslydescribed tetraparesis
in twodogs. Physical andneurological examinationswereunremarkable
in all examined 14 control German Hunting Terriers.
Laboratory ﬁndings
Complete blood cell counts were available for 22 German Hunting
Terriers (8 cases and 14 controls). All hematological values were within
the normal reference ranges. In contrast, chemistry proﬁles revealed
several abnormalities in affected dogs. Plasma creatine kinase (CK)
activity was signiﬁcantly higher in affected dogs (145-15,090 IU/l,
median 533 IU/l) than in controls (52-219 IU/l, median 71 IU/l; P =
0.0007). Similar ﬁndings were obtained regarding plasma alanine trans-
aminase (ALT) activities. Cases (44-2,705 IU/l, median 383 IU/l) had
signiﬁcantly higher ALT activity than controls (28-108 IU/l, median
63 IU/l; P = 0.002). The plasma lactate levels were only available for
19 dogs (7 cases and 12 controls). Cases (0.2-1.6 mmol/l, median
1.2 mmol/l) were not signiﬁcantly different from controls (0.1-
2.7 mmol/l, median 1.3 mmol/l; P = 0.3). All other chemistry param-
eters were in the respective reference ranges in the examined German
Hunting Terriers.
An acylcarnitine proﬁle was available for 22 dogs. Cases revealed a
prominent tetradecenoylcarnitine (C14:1) peak with a range from
0.5-2.6 mmol/l and a median of 1.3 mmol/l. In controls, virtually no
tetradecenoylcarnitine (C14:1) was detectable (0-0.1 mmol/l, median
0.0 mmol/l; P = 0.00004).
All eight cases excreted a dark brownish urine after exercise. In
comparison, urine of controls appeared normal. Urinalyis was in the
reference range. Brain natriuretic peptide (BNP) levels, marker for
myocardiac disease, were within the reference ranges in four affected
dogs tested.
Biopsy ﬁndings
Muscle samples harvested from the affected German Hunting Terriers
JT007 and JT009 revealed a mild to moderate necrotizing myopathy
with enrichment of interﬁbrillar lipid droplets and mitochondrial
abnormalities (Figure 1). Changes were widely spread and more
prominent in type 2 ﬁbers. Nerve biopsies from both dogs were un-
remarkable (not shown).
Genetic analysis
Given the results of the metabolic and histopathological analysis, the
ACADVL gene became the primary functional candidate gene for the
observed phenotype. In humans, ACADVLD has a strictly autosomal
recessive mode of inheritance. In agreement with our hypothesis, ped-
igree analysis of the extended German Hunting Terrier family strongly
suggested an autosomal recessive mode of inheritance. Both male and
female dogs were affected. The available cases belonged to ﬁve different
litters with unaffected parents. The pedigree of these dogs revealed
many inbreeding loops (Figure 2).
We performed whole genome sequencing on one affected dog and
called single nucleotide and small indel variants with respect to the
reference genome of a presumably unaffected Boxer (CanFam 3.1). We
searched for private homozygous protein-changing variants by com-
paring the variants in the case with the genomes of 3 wolves and
188 dogs from various breeds (Table S2). We did not have any speciﬁc
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information regarding a potential myopathy phenotype in the control
animals. However, as this is a rare condition, we assumed the control
dogs and wolves to be homozygous wildtype at the causative variant.
The variant calling pipeline detected more than 3 million homozy-
gous variants in the genome of the sequenced case. Of these, 23 were
absent from the control genomes and predicted to be protein changing.
One of them was located in the ACADVL gene, while the other 22 were
in genes that we did not consider to be likely functional candidate genes
(Table 2; Table S3). The ACADVL variant was a nonsense variant,
c.1728C.A, predicted to result in a premature stop codon that trun-
cates 80 amino acids from the C-terminus of the ACADVL protein.
The formal variant designation on the protein level is p.(Tyr576). The
variant was conﬁrmed by Sanger sequencing (Figure 3).
We then genotyped the variant in a cohort of 10 affected and
110 unaffected German Hunting Terriers. This revealed a perfect
association of the genotypes with the phenotype (Table 3). All
Figure 1 Myopathological char-
acteristics of German Hunting
Terriers with exercise induced
myopathy (A-H). On light micro-
scopic level, the muscles show
widespread individual myoﬁber
necroses (A,B: arrow) at active
(A) and resorptive/postresorp-
tive stages (B) surrounded by
normal myocytes (A,B: N). (C)
Necrotic ﬁbers (ﬁlled asterisks)
accumulate mitochondria that
appear red on Engel´s stain and
exhibit high activity of mitochon-
drial enzyme NADH-TR in histo-
chemical preparations (inlet;
black stain). Also non-necrotic ﬁ-
bers (empty asterisk) present
with prominent subsarcolemmal
and interﬁbrillar mitochondria if
compared to normal ﬁbers (C
main/inlet: N). (D) Fiber necroses
and atrophy both are predomi-
nantly recognized in fatiguable
fast-twitch type II ﬁbers (brown),
which parallels to relative type I
ﬁber (pale ﬁbers) enrichment.
Mitochondrial areas on semithin
sections (E) appear vacuolated
(frame: subsarcolemmal/perinu-
clear vacuolation; red arrows:
lined interﬁbrillar vacuoles),
which matches with the distribu-
tion of lipid droplets in oil red O
stained ﬁbers (F; black asterisk),
if compared to normal ﬁbers (N).
Ultrastructurally, both perinu-
clear (G) and interﬁbrillar (H) vac-
uolated areas contain masses of
dysmorphic mitochondria (white
asterisks) showing disorganized
cristae, trilaminar membranous
bodies (black asterisks) and
other electron dense inclusions
(blue arrow), as well as mem-
brane-bound lipid droplets (black
asterisks). Stains: (A,B): hematoxy-
lin-eosin, (C, main): Engel´s modi-
ﬁed Gomori, (C, inlet): NADH-TR,
(D): anti-fast myosin IHC, (E): azure
II methylenblue-safranin O, (F): oil
red O, (G,H): lead citrate-uranyl
acetate.
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10 affected dogs carried the variant in homozygous state. Five
available parents of affected dogs were heterozygous (obligate carriers;
Figure S1). The genotyped cohort was not necessarily representative for
the entire population as we preferentially collected close relatives of the
affected dogs. In a subset of 90 dogs that were not part of the extended
pedigree shown in Figure 2, we observed 15 heterozygous carriers
(17%). We also genotyped 435 dogs from genetically diverse breeds
(Table S1). None of these dogs carried the ACADVL:c.1728C.A
variant.
Genotype and phenotype correlation
We divided the 22 dogs with laboratory parameters in three groups
based on their ACADVL:c.1728C.A genotype and re-evaluated the
CK, ALT, C14:1 and plasma lactate levels (affected A/A, n = 8;
carrier C/A, n = 6; clear C/C, n = 8). The plasma lactate level did
not show any signiﬁcant differences between the three groups. CK,
ALT and C14:1 showed signiﬁcant differences between affected
dogs and either carriers or clear dogs. There were no statistically
signiﬁcant differences for CK, ALT and C14:1 between carriers and
clear dogs (Table 4; Figure 4).
DISCUSSION
This study comprised clinical, laboratory and histopathological exam-
inations to describe the phenotype of an inherited form of exercise
induced metabolic myopathy (EIMM) in German Hunting Terriers.
Figure 2 Pedigree of EIMM affected German Hunting Terriers used for this study. Filled symbols represent dogs with signs of myopathy. The gray
ﬁlled symbol indicates an owner-reported affected dog that was not clinically examined by one of the authors. Numbers indicate dogs from which
samples were available. The pedigree was drawn with a limited subset of animals for clarity. Multiple other inbreeding loops are not shown. It was
not possible to unambiguously identify the potential founder of the trait.
n Table 2 Variants detected by whole genome resequencing of an
affected German Hunting Terrier. Private variants were exclusively
present in the affected dog and had homozygous reference or
missing genotype calls in 191 control genomes
Filtering step Variantsa
Homozygous variants in whole genome 3,129,879
Private homozygous variants in the whole genome 2,555
Private protein changing homozygous variants in the
whole genome
23
Private protein changing homozygous variants in the
ACADVL gene
1
a
Only variants which passed the GATK quality ﬁlter were counted.
Figure 3 Sanger electropherograms of the ACADVL:c.1728C.A var-
iant. A genomic ACADVL fragment was ampliﬁed by PCR and se-
quenced with the Sanger method. The ﬁgure shows representative
data from dogs with the three different genotypes.
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A whole genome resequencing approach revealed the ACADVL:
c.1728C.A nonsense variant as candidate causative defect for the
observed phenotype.
Our claim of causality for the ACADVL:c.1728C.A variant is sup-
ported by three lines of evidence, perfect co-segregation of the mutant
allele in an extended family, perfect genotype-phenotype association in
a fairly large cohort of dogs, and the knowledge about the functional
impact of ACADVL variants in human patients.
We presented clinical data on three female and six male German
HuntingTerrier dogswith signs ofmyopathywith an age range between
7 to42months.Theobservedsigns includedmusclepain,weakness inall
four limbs and exercise induced intolerance after light strain in all nine
affected dogs. The diagnosis of myopathy is supported by the rhabdo-
myolysis found in themusclesbiopsiesand theelevatedplasmaCKlevels
in the affected dogs. CK is an enzyme which is mainly found in the
skeletal and cardiac muscle, as well as in the brain and the intestine. An
elevated CK level is widely used as marker for muscle cell damage as
CK is released into the circulation during cytolysis (Tvarijonaviciute
et al. 2017). Although no cardiac abnormalities were observed during
the clinical examination, plasma BNP levels, a cardiac marker used in
humans, dogs, and cats, weremeasured to assessmyocardium integrity in
four affected dogs and to exclude or include cardiovascular involvement
in the disease process (Andresen et al. 1999). All BNP values were within
the physiological limits. Rhabdomyolysis present in the biopsies of two
affected dogs supports the assumption that the elevated CK values found
in myopathic dogs are due to the observed pathological muscle changes.
Such ﬁndings are also present in the adult-onset form of ACADVLD in
humans. Given the absence of cardiac injury, we conclude that EIMM in
German Hunting Terriers clinically most closely resembles the adult-
onset form of the ACADVLD in humans (Andresen et al. 1999; Miller
et al. 2015). ALT is mostly a speciﬁc enzyme of the liver, but can also be
found in erythrocytes and skeletal muscle (Nelson and Couto 2014). We
observed that the affected dogs had signiﬁcantly increased plasma ALT
values in comparison to the non-myopathic dogs. As other liver function
indicators were all within the reference ranges and as the blood count did
not reveal any abnormalities, we assume that the liver integrity and the
erythrocytes were normal in the affected dogs. Therefore the observed
elevated ALT levels most likely reﬂect muscle damage. This ﬁnding also
supports the notion that the observed phenotype is similar to the adult-
onset form of ACADVLD in humans, as a liver disorder is only found
in the early-onset forms of human ACADVLD (Andresen et al. 1999;
Miller et al. 2015).
Using mass spectrometry we discovered a highly elevated level of
C14:1 in the acylcarnitine proﬁle in dogs with EIMM. An abnormal
elevation of long-chain acylcarnitine such as tetradecenoylcarnitine
(C14:1), is characteristic for an inherited disorder of mitochondrial
b-oxidation disorders such ACADVLD in humans (Tucci, 2017, Liang
and Nishino 2010). The routinely used human cutoff value for this
metabolite is 0.25 mmol/l. One published study in dogs suggested
a range of 0-0.14 mmol/l for adult healthy dogs (Osorio and Uribe-
Velásquez 2007). Our results conﬁrm that C14:1 can be used as labora-
torymarker for ACADVLD in dogs as there was a signiﬁcant difference
and no overlap between the affected and unaffected animals. EIMM
n Table 3 Association of the ACADVL:c.1728C>A genotypes with
myopathy
Genotype C/C C/A A/A
German Hunting Terriers with signs of myopathya — — 10
German Hunting Terrier controlsb 81 29 —
Dogs from other breeds 435 — —
a
9 clinically examined cases included.
b
14 clinically examined controls included.
n Table 4 Laboratory ﬁndings
Dog ID Sex
Age
(months)
Clinical signs
of myopathy
ACADVL:
c.1728C.A
genotype CK (IU/l)
a ALT (IU/l)a
C14:1
(mmol/l)a
Lactate
(mmol/l)a
Urine color
after strain
BNP
(pmol/l)a
JT007 m 32 yes A/A 15,090 402 1.1 1.4 brown n.d.
JT009 m 23 yes A/A 5,354 2,705 1.1 0.8 brown 250
JT033 m 23 yes A/A 2,174 602 2.4 n.d. brown 285
JT044 f 32 yes A/A 145 44 2.6 0.9 brown 356
JT045 f 32 yes A/A 185 364 1.4 ,0.2 brown 408
JT082 m 42 yes A/A 266 1,000 0.5 1.6 brown n.d.
JT112 m 42 yes A/A 799 305 1.1 1.2 brown n.d.
JT114 m 7 yes A/A 176 245 1.4 1.4 brown n.d.
JT005 f 96 no C/A 52 38 0.0 1.8 yellow n.d.
JT012 m 15 no C/A 103 98 0.1 1.2 yellow n.d.
JT013 m 70 no C/A 53 62 0.0 1.8 yellow n.d.
JT018 m 33 no C/A 64 89 0.1 1.1 yellow n.d.
JT019 m 56 no C/A 63 31 0.0 0.9 yellow n.d.
JT117 m 6 no C/A 219 36 0.0 ,0.1 yellow n.d.
JT008 f 119 no C/C 65 96 0.0 n.d. yellow n.d.
JT010 m 66 no C/C 88 73 0.0 n.d. yellow n.d.
JT015 f 50 no C/C 55 28 0.0 2.3 yellow n.d.
JT016 m 56 no C/C 74 56 0.0 1.8 yellow n.d.
JT017 m 55 no C/C 98 108 0.0 0.9 yellow n.d.
JT020 m 114 no C/C 68 82 0.0 1.4 yellow n.d.
JT021 m 126 no C/C 80 56 0.0 2.7 yellow n.d.
JT118 m 24 no C/C 194 64 0.0 0.8 yellow n.d.
a
Reference values in dog: CK = 48-400 IU/l; ALT = 18-86 IU/l; C14:1 = 0-0.14 mmol/l; lactate = 0.22-1.44 mmol/l; NT- proBNP # 900 pmol/l (Vaden 2009; Osorio and
Uribe-Velásquez 2007).
Volume 8 May 2018 | ACADVL Variant in Dogs | 1551
cases had tetradecenoylcarnitine (C14:1) levels $ 0.53 mmol/l
whereas all controls were # 0.10 mmol/l.
Lactate concentration was previously used to describe other lipid
storage myopathies caused by a pyruvate dehydrogenase deﬁciency
(Shelton et al. 1998). In our study, the plasma lactacte level was within
the reference ranges for all examined dogs. Somewhat unexpectedly,
there was no signiﬁcant difference between cases and controls. Since
lactate could not be measured immediately after exercise in the current
study, the relatively short half life of lactate could explain these ﬁndings
(Vaden 2009). Therefore, measurement of lactate levels is not recom-
mended as a marker for the ACADVLD in dogs.
The affected German Hunting Terriers presented a brownish dis-
coloration of the urine during or shortly after a collapsing episode. Such
pigmenturia is usually found during episodes of hemolysis due to the
presence of hemoglobin or erythrocytes in urine, or during episodes of
rhabdomyolysis andmyoglobinuria (Shelton 2004).We assume that the
observed brownish coloration of the urine was most likely caused by
the presence of myoglobin, in agreement with the results found in the
muscle biopsies. Episodes of rhabdomyolysis and myoglobinuria have
also been described for the adult-onset form of ACADVL deﬁciency in
humans and are signiﬁcant signs in previously healthy adults who
suddenly present with EIMM (Hoffman et al. 2006). This represents
another potential similarity of the observed phenotype in German
Hunting Terriers with ACADVLD in humans (Andresen et al. 1999;
Miller et al. 2015). The histopathological examination of the muscle
biopsies revealed lipid droplets within the muscle ﬁbers in addition to
the necrotizing myopathy. Similar accumulation of lipid droplets
withinmuscle ﬁbers is found in the adult-onset form in human patients
with ACADVLD (Liang and Nishino 2010, Liang and Nishino 2011).
Mitochondrial fatty acid oxidation is assumed to be similar in both
humansanddogs and the latter relyheavily on free fatty acidoxidationat
all levels of exercise intensity compared to humans (Hill 2010). Endur-
ance dogs, and here we includeGermanHuntingTerriers, primarily use
free fatty acid oxidation to provide ATP for exercise (Hill 2010).
Therefore, it is not surprising that a reduced or lacking activity of a
long-chain fatty acid oxidation enzyme would lead to severe exercise
intolerance given the fact that dogs preferentially mobilize long-chain
fatty acids during exercise (McClelland et al. 1995).
In humans, ACADVL variants may lead to autosomal recessive
ACADVLD (OMIM #201475). The EIMM in German Hunting Ter-
riers described in this study is also full recessive. Carrier dogs did not
show any detectable phenotypic difference in comparison to clear dogs.
We were not able to trace the affected animals back to a common
founder, suggesting that the ACADVL:c.1728C.A variant has been
present for several generations in the breed and may be quite wide-
spread. The canine ACADVL:c.1728C.A variant is located close to
the homologous position of three known human pathogenic variants,
p.Arg567Gln (eight cases, Schiff et al. 2013), p.Ser583Trp (three cases,
Souri et al. 1998) and p.Ser583Leu (three cases, Buján et al. 2014).
Moreover, human ACADVL frame-shift variants, comparable to
the dog variant, have also been described: p.Leu575Profs17 and
p.Met578Ilefs15 (Miller et al. 2015). Unfortunately, the human pa-
tients with these variants were not clearly classiﬁed into one of the three
forms of ACADVLD (Andresen et al. 1999). In humans, it was shown
that the C-terminal 180 amino acids of ACADVL play a role for homo-
dimer assembly and are important for the interaction between the pro-
tein and the inner membrane of the mitochondrion (Souri et al. 1998).
The clinical phenotype in the affected German Hunting Terriers
was comparatively mild and most closely resembled the adult form
of ACADVLD in humans. Further studies will be necessary to clarify
whether affected German Hunting Terriers retain some residual
ACADVL enzyme function. In a scenario with complete loss of
ACADVL function, the relativelymild phenotype in dogswould suggest
some physiological differences between humans and dogs that allow the
dogs to better compensate for the lack of ACADVL function. Alterna-
tively, as the dog variant is located near the end of theACADVL gene, in
the antepenultimate exon, it seems conceivable that a fraction of the
mutant transcripts might escape nonsense mediated decay and that the
truncated protein is actually expressed. The truncated protein is pre-
dicted to have an intact catalytical domain, which might give rise to
residual enzyme function, even if homodimer formation and/or the
interaction with the inner mitochondrial membrane are compromised.
Residual ACADVL enzyme function in homozygous mutant dogs
might also very well explain the relatively mild canine clinical pheno-
type. As mentioned above, further studies including protein function
studies are required to answer these open questions.
In conclusionwe discovered a novel hereditary disease andprovide a
ﬁrst description of the EIMM phenotype in German Hunting Terriers.
Furthermore, we identiﬁed a nonsense variant in the ACADVL gene as
most likely underlying genetic defect. Our ﬁndings provide a large
animal model for a known human disease and will enable genetic
testing to avoid the unintentional breeding of affected offspring.
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